This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
DJ Industrial : Wall Street Narrowly Mixed; Data, Fed Rate Meeting in Focus MT
Anchiano Therapeutics : Shareholders OK Pending Chemomab Merger MT
Anchiano Therapeutics Ltd.(NasdaqCM:ANCN) dropped from NASDAQ Composite Index CI
ChemomAb Ltd. completed the acquisition of Anchiano Therapeutics Ltd. in a reverse merger transaction. CI
Anchiano Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Anchiano Therapeutics Ltd. Auditor Raises 'Going Concern' Doubt CI
Anchiano Therapeutics : Chemomab Plan Merger to Advance Treatment for Fibrosis-Related Diseases MT
Anchiano Therapeutics Ltd. and Chemomab Ltd. Announce Executive Appointments CI
ChemomAb Ltd. entered into letter of intent to acquire Anchiano Therapeutics Ltd. for for $27.2 million in a reverse merger transaction. CI
Anchiano Therapeutics Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
Anchiano Therapeutics Ltd Appoints Neil Cohen as Chief Executive Officer CI
Anchiano Therapeutics Ltd Appoints Andrew Fine as the Chief Financial Officer CI
Anchiano Therapeutics Ltd Announces Board Changes CI
Anchiano Therapeutics Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
Anchiano Therapeutics Ltd Announces Resignation of Frank Haluska as CEO CI
Anchiano Therapeutics Ltd Announces Executive Changes CI
Frank Haluska to Resign as Director of Anchiano Therapeutics Ltd CI
Anchiano Appoints Stan Polovets as Chairman of the Board CI
Anchiano Therapeutics Ltd Announces Board Changes CI
Anchiano Therapeutics Ltd Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
Anchiano Therapeutics Ltd Announces Executive Changes CI
Anchiano Therapeutics Ltd Announces Board Elections CI
Anchiano Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2019 CI
Anchiano Therapeutics Ltd Auditor Raises 'Going Concern' Doubt CI
Anchiano Therapeutics Ltd Announces Resignation of Efrat Makov from Board of Directors CI
Chart Anchiano Therapeutics Ltd.
More charts
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. ANCN Stock
  4. News Anchiano Therapeutics Ltd.
  5. Anchiano Therapeutics : Shareholders OK Pending Chemomab Merger